Allogene Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Allogene Therapeutics, Inc. (ALLO) reported Increase (Decrease) in Accounts Payable of $1.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-12
- Allogene Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $1.03M.
- Allogene Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $663.00K.
- Allogene Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $599.00K, a 1661.76% increase year-over-year.
- Allogene Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.07M.
- Allogene Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$1.23M.
- Allogene Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$503.00K.
- Allogene Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$7.50M, a 254.11% decline from fiscal 2022.
- Allogene Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $4.87M.
| Period end | Increase (Decrease) in Accounts Payable 1 month | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.69M 10-Q · filed 2026-08-12 | $2.29M derived: sum of 3 quarters · filed 2026-08-12 | $1.22M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $663.00K 10-Q · filed 2026-05-13 | $1.26M derived: sum of 2 quarters · filed 2026-05-13 | $190.00K derived: sum of 3 quarters · filed 2026-05-13 | -$232.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $599.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$473.00K derived: sum of 2 quarters · filed 2026-03-12 | -$895.00K derived: sum of 3 quarters · filed 2026-08-12 | -$1.23M 10-K · filed 2026-03-12 | |
| 2025-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.49M derived: sum of 2 quarters · filed 2026-08-12 | -$1.83M 10-Q · filed 2025-11-06 | -$1.80M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$422.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$758.00K 10-Q · filed 2026-08-12 | -$724.00K derived: sum of 3 quarters · filed 2026-08-12 | -$7.95M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$336.00K 10-Q · filed 2026-05-13 | -$302.00K derived: sum of 2 quarters · filed 2026-05-13 | -$7.53M derived: sum of 3 quarters · filed 2026-05-13 | -$721.00K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$7.19M derived: sum of 2 quarters · filed 2026-03-12 | -$385.00K derived: sum of 3 quarters · filed 2026-03-12 | -$503.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$7.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$419.00K derived: sum of 2 quarters · filed 2025-11-06 | -$537.00K 10-Q · filed 2025-11-06 | -$839.00K derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $6.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $6.69M 10-Q · filed 2025-08-13 | $6.39M derived: sum of 3 quarters · filed 2025-08-13 | $2.42M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$118.00K 10-Q · filed 2025-05-13 | -$420.00K derived: sum of 2 quarters · filed 2025-05-13 | -$4.39M derived: sum of 3 quarters · filed 2025-05-13 | -$8.68M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | -$302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$4.27M derived: sum of 2 quarters · filed 2025-03-13 | -$8.56M derived: sum of 3 quarters · filed 2025-03-13 | -$7.50M 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$3.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$8.26M derived: sum of 2 quarters · filed 2024-11-07 | -$7.20M 10-Q · filed 2024-11-07 | -$4.26M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$4.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$3.23M 10-Q · filed 2024-08-07 | -$295.00K derived: sum of 3 quarters · filed 2024-08-07 | $718.00K derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $1.06M 10-Q · filed 2024-05-13 | $4.00M derived: sum of 2 quarters · filed 2024-05-13 | $5.01M derived: sum of 3 quarters · filed 2024-05-13 | $6.43M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $2.94M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $3.95M derived: sum of 2 quarters · filed 2024-03-14 | $5.37M derived: sum of 3 quarters · filed 2024-03-14 | $4.87M 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.44M derived: sum of 2 quarters · filed 2023-11-02 | $1.93M 10-Q · filed 2023-11-02 | -$114.00K derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $917.00K 10-Q · filed 2023-08-02 | -$1.13M derived: sum of 3 quarters · filed 2024-03-14 | -$938.00K derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | -$505.00K 10-Q · filed 2023-05-03 | -$2.55M derived: sum of 2 quarters · filed 2024-03-14 | -$2.36M derived: sum of 3 quarters · filed 2024-03-14 | -$5.42M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | -$2.04M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | -$1.85M derived: sum of 2 quarters · filed 2024-03-14 | -$4.92M derived: sum of 3 quarters · filed 2024-03-14 | -$767.00K 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | $189.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$2.88M derived: sum of 2 quarters · filed 2022-11-02 | $1.28M 10-Q · filed 2022-11-02 | $211.00K derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | -$3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.09M 10-Q · filed 2022-08-09 | $22.00K derived: sum of 3 quarters · filed 2024-03-14 | $2.21M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | $4.15M 10-Q · filed 2022-05-04 | $3.09M derived: sum of 2 quarters · filed 2024-03-14 | $5.27M derived: sum of 3 quarters · filed 2024-03-14 | $5.81M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | -$1.07M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $1.12M derived: sum of 2 quarters · filed 2024-03-14 | $1.66M derived: sum of 3 quarters · filed 2024-03-14 | $615.00K 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | $2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.73M derived: sum of 2 quarters · filed 2021-11-04 | $1.68M 10-Q · filed 2021-11-04 | $3.83M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-06-30 | $541.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$503.00K 10-Q · filed 2021-08-04 | $1.65M derived: sum of 3 quarters · filed 2022-02-23 | -$2.82M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | -$1.04M 10-Q · filed 2021-05-05 | $1.11M derived: sum of 2 quarters · filed 2022-02-23 | -$3.36M derived: sum of 3 quarters · filed 2022-02-23 | -$1.68M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$2.32M derived: sum of 2 quarters · filed 2022-02-23 | -$637.00K derived: sum of 3 quarters · filed 2022-02-23 | -$985.00K 10-K · filed 2022-02-23 | |
| 2019-09-30 | -$4.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$2.79M derived: sum of 2 quarters · filed 2020-11-04 | -$3.14M 10-Q · filed 2020-11-04 | $2.58M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.33M 10-Q · filed 2020-08-05 | $7.05M derived: sum of 3 quarters · filed 2021-02-25 | $8.86M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$348.00K 10-Q · filed 2020-05-06 | $5.37M derived: sum of 2 quarters · filed 2021-02-25 | $7.18M derived: sum of 3 quarters · filed 2021-02-25 | $8.45M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $5.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $7.53M derived: sum of 2 quarters · filed 2021-02-25 | $8.80M derived: sum of 3 quarters · filed 2021-02-25 | $8.80M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $3.08M derived: sum of 2 quarters · filed 2019-11-05 | $3.08M 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $1.27M 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |